AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Cambium Bio Limited

0.570

0.000

Volume:- -

Turnover:- -

Market Cap:13.09M

PE:-2.71

High:0.570

Open:0.570

Low:0.570

Close:0.570

52wk High:0.640

52wk Low:0.190

Shares:22.97M

Float Shares:4.29M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.210

EPS(LYR):-0.006

ROE:--

ROA:--

PB:--

PE(LYR):-103.56

Loading ...

Overview Company News Filings

Thunes and UnionPay International Launch Instant Money Transfers to China's mainland

BUZZ-Australia's Cambium Bio hits 7-week high on premium placement

Cambium Bio - Receives a$2.4 Mln Investment From Zheng Yang Biomedical Technology

THOMSON REUTERS

Cambium Bio Ltd-Change of Directors Interest Notice - TW

THOMSON REUTERS

Cambium Bio Ltd-Change of Directors Interest Notice - Ew

THOMSON REUTERS

BRIEF-Cambium Bio Signs MoU With Locus Cell For Manufacturing Of Elate Ocular

Cambium Bio Executes Agreement for Contract Manufacturing of Active Biologic Ingredient for Therapy Candidate

MT Newswires Live

Cambium Bio - Signs Mou With Locus Cell for Manufacturing of Elate Ocular

THOMSON REUTERS

Locus Cell's Zhubei Smart GMP Facility Secures First International Phase III CDMO Manufacturing MOU with Cambium Bio

Cambium Bio Forms Partnership With French Pharmaceutical Firm; Shares Up 4%

MT Newswires Live

BUZZ-Australia's Cambium Bio advances on signing MoU for Elate Ocular

Cambium Bio Ltd - Signs Mou With Benta Sas for Elate Ocular

THOMSON REUTERS

Cambium Bio Signs Licensing Deal for Fibrin Biologic in Dental Applications

MT Newswires Live

Cambium Bio - Signs $2.0M Licensing Deal for Fibrin Biologic in Dental Applications

THOMSON REUTERS

BRIEF-Cambium Bio To Raise A$2.12 Million Through Placement

Cambium Bio Ltd - to Raise a$2.12 Mln Through Placement at a$0.4637 per Share

THOMSON REUTERS

Cambium Bio Ltd-Proposed Issue of Securities - Cmb

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CMB.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CMB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CMB.AU\",,,,,undefined,":{"symbol":"CMB.AU","market":"AU","secType":"STK","nameCN":"Cambium Bio Limited","latestPrice":0.57,"timestamp":1770700260134,"preClose":0.57,"halted":0,"volume":0,"delay":0,"changeRate":0,"nameEN":"Cambium Bio Limited","floatShares":4291164,"shares":22968281,"eps":-0.21,"marketStatus":"Post Close","change":0,"latestTime":"02-10 16:13:42 AEDT","open":0.57,"high":0.57,"low":0.57,"amount":0,"amplitude":0,"askPrice":0.57,"askSize":1400,"bidPrice":0.52,"bidSize":1294,"shortable":3,"etf":0,"ttmEps":-0.21,"tradingStatus":3,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1770764400000},"marketStatusCode":15,"adr":0,"exchange":"ASX","adjPreClose":0.57,"openAndCloseTimeList":[[1770678000000,1770699600000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CMB.AU\",,,,,undefined,":{"symbol":"CMB.AU","floatShares":4291164,"roa":"--","roe":"--","lyrEps":-0.005504,"shares":22968281,"dividePrice":0,"high":0.57,"amplitude":0,"preClose":0.57,"low":0.57,"week52Low":0.19,"pbRate":"--","week52High":0.64,"institutionHeld":0,"latestPrice":0.57,"committee":-0.039347,"eps":-0.21,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.21,"open":0.57,"prevYearClose":0.47,"prevWeekClose":0.59,"prevMonthClose":0.585,"prevQuarterClose":0.47,"fiveDayClose":0.6,"twentyDayClose":0.46,"sixtyDayClose":0.51},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CMB.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-07-04","symbol":"CMB.AU","defaultRemindTime":1720051200000,"type":"split","dateTimestamp":1720015200000,"forFactor":100,"toFactor":1,"ratio":100}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CMB.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CMB.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2605823465","title":"Thunes and UnionPay International Launch Instant Money Transfers to China's mainland","url":"https://stock-news.laohu8.com/highlight/detail?id=2605823465","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605823465?lang=en_us&edition=fundamental","pubTime":"2026-01-22 16:00","pubTimestamp":1769068800,"startTime":"0","endTime":"0","summary":"SINGAPORE and SHANGHAI, Jan. 22, 2026 /PRNewswire/ --Thunes, the Smart Superhighway to move money around the world, today announces the launch of faster, more reliable, and more transparent payments into China's mainland following a deepened collaboration with UnionPay International .Despite being the world's second-largest economy, sending money to China has traditionally been complex, and hindered by hidden fees and the need for recipients to manually declare funds. Thunes' direct connection to UnionPay resolves these frictions. By connecting directly, the collaboration between UnionPay and Thunes enables a seamless Pay-to-Card experience where transactions are credited in real-time or within 12 hours.UnionPay MoneyExpress is a cornerstone of UnionPay International's cross-border remittance strategy, providing a secure and efficient way for funds to reach China's mainland. The collaboration with Thunes strengthens the bridge between global financial institutions and Chinese cardholde","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/thunes-and-unionpay-international-launch-instant-money-transfers-to-chinas-mainland-302667122.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABC.AU","BK7044","BK7067","CCB","BK4211","CMB.AU"],"gpt_icon":0},{"id":"2604154644","title":"BUZZ-Australia's Cambium Bio hits 7-week high on premium placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2604154644","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604154644?lang=en_us&edition=fundamental","pubTime":"2026-01-20 08:58","pubTimestamp":1768870699,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Cambium Bio hits 7-week high on premium placement** Cambium Bio CMB.AX jumps 13% to A$0.52, highest since November 27, 2025** Regenerative medicine co secures A$2.4 million strategic investment from major shareholder Zheng Yang Biomedical Technology Co** Investment via placement of 4.4 mln new shares at A$0.55/share, representing 19.6% premium to last close** YTD, CMB up 10.6%  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nL6N3YL022:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CMB.AU"],"gpt_icon":0},{"id":"2604153778","title":"Cambium Bio - Receives a$2.4 Mln Investment From Zheng Yang Biomedical Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2604153778","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604153778?lang=en_us&edition=fundamental","pubTime":"2026-01-20 05:19","pubTimestamp":1768857576,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260119:nFWN3YK0MV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMB.AU","BK7067"],"gpt_icon":0},{"id":"2577153495","title":"Cambium Bio Ltd-Change of Directors Interest Notice - TW","url":"https://stock-news.laohu8.com/highlight/detail?id=2577153495","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577153495?lang=en_us&edition=fundamental","pubTime":"2025-10-24 05:18","pubTimestamp":1761254302,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nTUE5V61DT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CMB.AU"],"gpt_icon":0},{"id":"2577534952","title":"Cambium Bio Ltd-Change of Directors Interest Notice - Ew","url":"https://stock-news.laohu8.com/highlight/detail?id=2577534952","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577534952?lang=en_us&edition=fundamental","pubTime":"2025-10-24 05:18","pubTimestamp":1761254292,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nTUE13QGTJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMB.AU","BK7067"],"gpt_icon":0},{"id":"2571434689","title":"BRIEF-Cambium Bio Signs MoU With Locus Cell For Manufacturing Of Elate Ocular","url":"https://stock-news.laohu8.com/highlight/detail?id=2571434689","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571434689?lang=en_us&edition=fundamental","pubTime":"2025-09-30 18:25","pubTimestamp":1759227942,"startTime":"0","endTime":"0","summary":"BRIEF-Cambium Bio Signs MoU With Locus Cell For Manufacturing Of Elate OcularSept 30 (Reuters) - Cambium Bio Ltd CMB.AX:SIGNS MOU WITH LOCUS CELL FOR MANUFACTURING OF ELATE OCULARFurther company coverage: CMB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nFWN3VG0M2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMB.AU","BK7067"],"gpt_icon":0},{"id":"2571394085","title":"Cambium Bio Executes Agreement for Contract Manufacturing of Active Biologic Ingredient for Therapy Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2571394085","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571394085?lang=en_us&edition=fundamental","pubTime":"2025-09-30 12:17","pubTimestamp":1759205825,"startTime":"0","endTime":"0","summary":"Cambium Bio  executed a memorandum of understanding with Taiwan-based Locus Cell for the contract manufacturing of the active biologic ingredient for Elate Ocular, its lead dry eye disease therapy candidate, according to a Tuesday Australian bourse filing.Locus Cell will manufacture the active biologic ingredient, the drug substance component of Elate Ocular, based on pooled fibrinogen-depleted human platelet lysates.Zheng Yang Biomedical Technology, as Cambium's technology partner, will provide manufacturing protocols and conduct technical transfer to Locus Cell. Zheng Yang holds around 28.1% stake in Cambium.The manufacturing rights cover worldwide markets except Europe and the Middle East. Supply will be exclusively to Cambium or its designees under future definitive supply and quality deals. The agreement has a two-year initial term with mutual extension options.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","CMB.AU"],"gpt_icon":0},{"id":"2571391933","title":"Cambium Bio - Signs Mou With Locus Cell for Manufacturing of Elate Ocular","url":"https://stock-news.laohu8.com/highlight/detail?id=2571391933","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571391933?lang=en_us&edition=fundamental","pubTime":"2025-09-30 11:33","pubTimestamp":1759203188,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nFWN3VG0M2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMB.AU","BK7067"],"gpt_icon":0},{"id":"2571361332","title":"Locus Cell's Zhubei Smart GMP Facility Secures First International Phase III CDMO Manufacturing MOU with Cambium Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2571361332","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571361332?lang=en_us&edition=fundamental","pubTime":"2025-09-30 07:00","pubTimestamp":1759186800,"startTime":"0","endTime":"0","summary":"TAIPEI, Sept. 30, 2025 /PRNewswire/ -- Locus Cell , a leading regenerative medicine CDMO in Taiwan, announced it has signed a Memorandum of Understanding  with Australia-based Cambium Bio . Under the agreement, Cambium will entrust Locus Cell with the contract development and manufacturing  of Elate Ocular -related. Elate Ocular, a Phase III dry eye disease therapy currently under clinical trials in Taiwan, the U.S., and Australia. The technology originates from Cambium's parent company,Zheng Yang Biomedical Technology Co., Ltd.Locus Cell’s Zhubei Smart GMP Facility Secures Its First International Phase III CDMO Manufacturing MOU. From left: Karolis Rosickas, CEO of Cambium Bio; Yu-Hung Tseng, Chairman of Zheng Yang Biomedical Technology Co., Ltd.; and Jiunn-Rong Chiou, Chairman of Locus Cell.","market":"fut","thumbnail":"https://mma.prnewswire.com/media/2783933/Locus_Cell_s_Zhubei_Smart_GMP_Facility_Secures_Its_First_International_Phase_III_CDMO_Manufacturing.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2783933/Locus_Cell_s_Zhubei_Smart_GMP_Facility_Secures_Its_First_International_Phase_III_CDMO_Manufacturing.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/locus-cells-zhubei-smart-gmp-facility-secures-first-international-phase-iii-cdmo-manufacturing-mou-with-cambium-bio-302569079.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["III","BK4134","CMB.AU","BK7067","BK4139","CDMO"],"gpt_icon":0},{"id":"2565469536","title":"Cambium Bio Forms Partnership With French Pharmaceutical Firm; Shares Up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2565469536","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565469536?lang=en_us&edition=fundamental","pubTime":"2025-09-05 12:28","pubTimestamp":1757046499,"startTime":"0","endTime":"0","summary":"Cambium Bio  entered into a memorandum of understanding with Benta, a French pharmaceutical company, to establish a strategic partnership to develop and commercialize Elate Ocular for dry eye disease in Europe and the Middle East, according to a Friday Australian bourse filing.The company said the partnership will provide access to major European and Middle Eastern markets. Under the deal, Benta will facilitate exchanges with regulators in France and Europe, the Middle East, and Africa.The company's shares rose past 4% in recent Friday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CMB.AU","BK7067"],"gpt_icon":0},{"id":"2565533562","title":"BUZZ-Australia's Cambium Bio advances on signing MoU for Elate Ocular","url":"https://stock-news.laohu8.com/highlight/detail?id=2565533562","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565533562?lang=en_us&edition=fundamental","pubTime":"2025-09-05 11:09","pubTimestamp":1757041795,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Cambium Bio advances on signing MoU for Elate Ocular** Shares of Australia's Cambium Bio CMB.AX rise as much as 15.8% to A$0.55** Stock has gained 5.3% so far in the week, on track to record its second consecutive week of gains, if the trend holds** Regenerative medicine firm signs memorandum of understanding  with French pharma company Benta SAS** MoU to establish a strategic partnership for the development and commercialisation of Elate Ocular  for dry eye disease in Europe and the Middle East** Stock has risen 23.8% this year, as of 0304 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250905:nL4N3US077:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CMB.AU"],"gpt_icon":0},{"id":"2565874155","title":"Cambium Bio Ltd - Signs Mou With Benta Sas for Elate Ocular","url":"https://stock-news.laohu8.com/highlight/detail?id=2565874155","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565874155?lang=en_us&edition=fundamental","pubTime":"2025-09-05 09:37","pubTimestamp":1757036279,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250905:nFWN3UR120:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMB.AU","BK7067"],"gpt_icon":0},{"id":"2564876311","title":"Cambium Bio Signs Licensing Deal for Fibrin Biologic in Dental Applications","url":"https://stock-news.laohu8.com/highlight/detail?id=2564876311","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564876311?lang=en_us&edition=fundamental","pubTime":"2025-09-02 14:36","pubTimestamp":1756794995,"startTime":"0","endTime":"0","summary":"Cambium Bio  has entered into a term sheet with Keke Medtech, granting exclusive worldwide rights to develop and commercialize the company's proprietary human platelet lysate-derived fibrin biologic product for dental and oral wound healing applications, according to a Tuesday Australian bourse filing.The deal includes an upfront payment of $250,000, of which $25,000 has already been received.The deal also includes development milestones of up to $1.75 million and 10% royalties on the first $10 million and 13% thereafter.The company will also receive a 20% share of non-royalty sublicense revenues.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CMB.AU","BK7067"],"gpt_icon":0},{"id":"2564225388","title":"Cambium Bio - Signs $2.0M Licensing Deal for Fibrin Biologic in Dental Applications","url":"https://stock-news.laohu8.com/highlight/detail?id=2564225388","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564225388?lang=en_us&edition=fundamental","pubTime":"2025-09-02 11:08","pubTimestamp":1756782486,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nFWN3UO0EG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CMB.AU"],"gpt_icon":0},{"id":"2555939700","title":"BRIEF-Cambium Bio To Raise A$2.12 Million Through Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2555939700","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555939700?lang=en_us&edition=fundamental","pubTime":"2025-07-30 09:45","pubTimestamp":1753839911,"startTime":"0","endTime":"0","summary":"BRIEF-Cambium Bio To Raise A$2.12 Million Through PlacementJuly 30 (Reuters) - Cambium Bio Ltd CMB.AX:TO RAISE A$2.12 MILLION THROUGH PLACEMENT AT A$0.4637 PER SHAREFurther company coverage: CMB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nFWN3TQ1HM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CMB.AU"],"gpt_icon":0},{"id":"2555098597","title":"Cambium Bio Ltd -  to Raise a$2.12 Mln Through Placement at a$0.4637 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2555098597","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555098597?lang=en_us&edition=fundamental","pubTime":"2025-07-30 09:15","pubTimestamp":1753838132,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nFWN3TQ1HM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMB.AU","BK7067"],"gpt_icon":0},{"id":"2555983270","title":"Cambium Bio Ltd-Proposed Issue of Securities - Cmb","url":"https://stock-news.laohu8.com/highlight/detail?id=2555983270","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555983270?lang=en_us&edition=fundamental","pubTime":"2025-07-30 09:14","pubTimestamp":1753838096,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nTUEBZ7LX6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMB.AU","BK7067"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":17,"code":"91000000","status":"200"}]}}